Enlivex Therapeutics Ltd.
NASDAQ:ENLVBiotechnology
+$0.19 today
- Market cap
- $71.70M
- Beta
- 1.52
- P/E (TTM)
- 0.0
- EPS (TTM)
- $407.81
Volume 0.06M
Average 0.44M
ENLV Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
Enlivex Therapeutics Ltd.NASDAQ: ENLV
Short-term Investments · Q4 FY2025 · quarter ended Dec 2025
Short-term investments falls 80.9% from a year ago
Short-term investments stood at $3.86M at the end of Q4 FY2025, down 80.9% from a year earlier and down 72.7% from the prior quarter. Over 3 fiscal years it compounded at +134.6% a year.
Context
- Short-term investments amounted to 0.2% of total assets at the end of Q4 FY2025, down 72.8 pp from a year earlier.
- Short-term investments increased in 1 of the last 3 fiscal years.
What to watch
Whether short-term investments keeps falling in the next quarterly balance sheet after a -80.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 3.86M USD
- Year-over-year change
- -80.9%
- 4-year CAGR
- -52.0%
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.86M | -80.9% |
| FY2024 | 2024-12-31 | 20.2M | -23.8% |
| FY2023 | 2023-12-31 | 26.51M | +8765.2% |
| FY2022 | 2022-12-31 | 299K | -99.6% |
| FY2021 | 2021-12-31 | 72.93M | — |
Short-term Investments vs competitors
How ENLV compares with its peers on the latest reported figures
- ENLV's Dec 2025 short-term investments of $3.86M is the highest of the 2 companies compared; the peer median is $0.
- Short-term investments amounts to 0.2% of total assets for ENLV, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | $3.86M | -80.9% | +134.6% | 0.2% | |
NRXSNeurAxis, Inc. | Mar 2026 | $0 | — | — | 0.0% |
| Peer median (excluding ENLV) | $0 | — | — | 0.0% | |
Competitors are the stored peer set for ENLV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 11.2M | 49.95M | 813K | 3.3M | 2.01M |
| Short-term Investments | 72.93M | 299K | 26.51M | 20.2M | 3.86M |
| Net Receivables | 1.09M | 647K | 229K | 1.3M | 235K |
| Inventory | 0 | 1.18M | 0 | 0 | 0 |
| Other Current Assets | 113K | (1.18M) | 5.11M | 198K | 1.73B |
| Total Current Assets | 86.44M | 52.33M | 33.76M | 25.99M | 1.74B |
| Property, Plant & Equipment (Net) | 8.22M | 14.9M | 2.58M | 1.15M | 938K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 582.51M |
| Long-term Investments | 3K | 0 | 308K | 531K | 374K |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 482K | 412K | 179K | 10K | 0 |
| Total Non-current Assets | 8.7M | 15.31M | 3.07M | 1.69M | 583.82M |
| Total Assets | 95.15M | 67.64M | 36.83M | 27.69M | 2.33B |
| Account Payables | 878K | 1.95M | 827K | 811K | 3.81M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 1.57M | 142K | 1.89M |
| Total Current Liabilities | 4.72M | 6.61M | 6.06M | 3.8M | 9.02M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 382.65M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 5.39M | 4.19M | 686K | 299K | 383.03M |
| Total Liabilities | 10.11M | 10.8M | 6.75M | 4.1M | 392.05M |
| Common Stock | 2.11M | 2.12M | 2.14M | 2.69M | 28.73M |
| Retained Earnings | (51.97M) | (83.03M) | (112.09M) | (127.11M) | 1.11B |
| Accumulated OCI | 1.1M | 1.1M | 1.1M | 1.1M | 1.1M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 85.04M | 56.84M | 30.08M | 23.59M | 1.93B |
| Total Debt | 6.01M | 4.85M | 1.03M | 534K | 641K |
| Net Debt | (5.2M) | (45.1M) | 219K | (2.77M) | (1.37M) |
Enlivex Therapeutics Ltd.
NASDAQ:ENLV
Intrinsic Alpha fair value
Locked
Current Price
$4.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.